Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma

BackgroundNeoadjuvant checkpoint inhibition (CPI) has recently demonstrated impressive outcomes in patients with stage 3 cutaneous melanoma. However, the safety, efficacy, and outcome of neoadjuvant CPI in patients with mucosal melanoma (MM) are not well studied as MM is a rare melanoma subtype. CPI...

Full description

Bibliographic Details
Main Authors: Joel Ho, Jane Mattei, Michael Tetzlaff, Michelle D. Williams, Michael A. Davies, Adi Diab, Isabella C. Glitza Oliva, Jennifer McQuade, Sapna P. Patel, Hussein Tawbi, Michael K. Wong, Sarah B. Fisher, Ehab Hanna, Emily Z. Keung, Merrick Ross, Roi Weiser, Shirley Y. Su, Michael Frumovitz, Larissa A. Meyer, Amir Jazaeri, Curtis A. Pettaway, B. Ashleigh Guadagnolo, Andrew J. Bishop, Devarati Mitra, Ahsan Farooqi, Roland Bassett, Silvana Faria, Priyadharsini Nagarajan, Rodabe N. Amaria
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
mucosal melanoma
immunotherapy
melanoma
neoadjuvant
resectable
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1001150/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1001150/full

Similar Items